title: Relationship between New York Heart Association class change and ventricular tachyarrhythmia occurrence in patients treated with cardiac resynchronization plus defibrillator.
abstract: OBJECTIVE
  In patients with advanced heart failure (HF) and prolonged QRS interval, cardiac resynchronization therapy (CRT) reduces symptoms and risk of death. The added benefit of an implantable cardioverter defibrillator (ICD) remains questionable in some patients.
  
  
  RESULTS
  In 332 HF patients treated with CRT-D (CRT with ICD) [65 +/- 10 years, 86% men, 23% New York Heart Association (NYHA) class II, 65% class III, and 11% class IV, 70% primary prevention, 55% ischaemic cardiomyopathy, left ventricular ejection fraction 25 +/- 7.5%, and QRS width 167 +/- 32 ms], we evaluated the relationship between functional status change, death at 6-month follow-up (FU), and the occurrence of ventricular tachyarrhythmia/ventricular fibrillation (VT/VF). A total of 68 patients (20.5%) experienced 1266 spontaneous episodes of VT/VF during FU. There was no difference in baseline characteristics between patients with or without VT/VF, except for ICD indication (primary or secondary prevention). Improvement in NYHA class was significantly associated with a decreased occurrence of VT/VF (P = 0.004). Sixteen patients who died had significantly more often VT/VF than the survivors (50 vs. 19%, P = 0.007).
  
  
  CONCLUSIONS
  Within the initial 6-month post-CRT therapy, 20% of patients received an appropriate ICD therapy. Patients improving on NYHA class (responders to CRT) have less VT/VF episodes than non-responders. Discriminant criteria for CRT response are awaited to optimize the choice of the device (CRT alone, defibrillator alone, or CRT-D).
authors.affiliation: Centre Cardiologique du Nord, 26 rue des Moulins Gémeaux 93200, Saint-Denis, France. alepillier@hotmail.com
authors.forename: Antoine
authors.initials: A
authors.lastname: Lepillier
authors.forename: Olivier
authors.initials: O
authors.lastname: Piot
authors.forename: Bart
authors.initials: B
authors.lastname: Gerritse
authors.forename: Xavier
authors.initials: X
authors.lastname: Copie
authors.forename: Thomas
authors.initials: T
authors.lastname: Lavergne
authors.forename: Olivier
authors.initials: O
authors.lastname: Paziaud
authors.forename: Gilles
authors.initials: G
authors.lastname: Lascault
authors.forename: Xavier
authors.initials: X
authors.lastname: Waintraub
authors.forename: Akli
authors.initials: A
authors.lastname: Otmani
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Le Heuzey
mesh_terms: D000368:Aged; D002304:Cardiac Pacing, Artificial / Q000401:mortality*; D017147:Defibrillators, Implantable / Q000706:statistics & numerical data*; D005060:Europe / Q000453:epidemiology; D005260:Female; D006333:Heart Failure / Q000401:mortality* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D015995:Prevalence; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D013223:Statistics as Topic; D016019:Survival Analysis; D015996:Survival Rate; D017180:Tachycardia, Ventricular / Q000401:mortality* / Q000517:prevention & control*; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000401:mortality / Q000517:prevention & control